Pacific Biosciences Of California (PACB) Short term Debt (2010 - 2023)

Pacific Biosciences Of California has reported Short term Debt for 6 years, with the latest figure at $96.2 million in Q3 2023.

• For the quarter ending Q3 2023, Short term Debt changed N/A year-over-year to $96.2 million; the trailing twelve-month figure through Sep 2023 stood at $96.2 million (changed N/A YoY), and the FY2022 full-year result was $172.1 million, up 10602.36% from the prior year.
• Short term Debt for Q3 2023 stood at $96.2 million, down from $186.3 million in the prior quarter.
• The five-year high for Short term Debt was $186.3 million in Q2 2023, with the low at $1.6 million in Q4 2021.
• Average Short term Debt over 3 years is $128.1 million, with a median of $172.1 million recorded in 2022.
• Peak annual rise in Short term Debt reached 10602.36% in 2022, while the deepest fall reached 10602.36% in 2022.
• Tracing PACB's Short term Debt over 3 years: stood at $1.6 million in 2021, then surged by 10602.36% to $172.1 million in 2022, then tumbled by 44.1% to $96.2 million in 2023.
• The last three Short term Debt figures came in at $96.2 million (Q3 2023), $186.3 million (Q2 2023), and $184.4 million (Q1 2023), per Business Quant data.

Peer Comparison